宜宾哪纹眼线好宜宾微整隆鼻玻尿酸要多少钱,宜宾玻尿酸全脸填充多少钱,玻尿酸下巴费用宜宾,宜宾整形美容医院韩式定位双眼皮,宜宾假体丰胸价格一般多少,宜宾疤痕体质割双眼皮,宜宾脂肪丰胸真实图片

ISLAMABAD, Oct. 24 (Xinhua) -- Samina, 38, was shocked when doctor told her that she has been suffering from breast cancer for three years and due to late diagnosis the disease spread into her bones making the chances of survival very slim.Samina said that she is trying hard to fight the disease, at the same time she holds the doctors of her village responsible for failing to diagnose the disease in three long years. She is also concerned about her three kids too young to accept any bitter reality."I can't see the distressed faces of my children, I can't bear the fear that looms in their eyes, they know that with every coming day their mother is moving a step forward to death," Samina told Xinhua in a very low tone.When Samina and all other patients of that gloomy medical ward for breast cancer patients, in Nuclear Medicine Oncology and Radiography (NORI) hospital in Islamabad, were told that October is being observed as breast cancer awareness month they murmured that the awareness message should be reached to every nook and corner of the country this year so that no other woman would die due to unawareness.In a country like Pakistan where one in nine women is prone to breast cancer and around 40,000 women die every year due to lack of awareness of this disease. They come to visit oncology department of hospitals at a stage when the chances of survival are very remote.Omer Aftab, National Coordinator of the Pink Ribbon, said that Pakistan has the highest rate of breast cancer among Asian nations. It is the most common malignancy in women, and accounts for 38.5 percent of all female cancer patients, with 90,000 new cases every year.

WASHINGTON, Nov. 24 (Xinhua) -- An inexpensive drug that treats Type 2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State University researcher. The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides biological evidence for previously reported epidemiological surveys that long-term use of the drug metformin for Type 2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.The research appeared online this week in PLoS One.For the study, Trosko and colleagues focused on the concept that cancers originate from adult human stem cells and that there are many natural and man-made chemicals that enhance the growth of breast cancer cells. Using culture dishes, they grew miniature human breast tumors, or mammospheres, that activated a certain stem cell gene. Then the mammospheres were exposed to natural estrogen -- a known growth factor and potential breast tumor promoter -- and man-made chemicals that are known to promote tumors or disrupt the endocrine system.The team found that estrogen and the chemicals caused the mammospheres to increase in numbers and size. However, with metformin added, the numbers and size of the mammospheres were dramatically reduced. While each of the chemicals enhanced growth by different means, metformin seemed to be able to inhibit their stimulated growth in all cases."While future studies are needed to understand the exact mechanism by which metformin works to reduce the growth of breast cancers, this study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers," Trosko said.

SAN FRANCISCO, Nov. 11 (Xinhua) -- Logitech, a provider of personal peripherals for computers and other digital platforms, said its production of Google TV was a "big mistake," giving a major blow to Google's aspiration to change the traditional TV experience, U.S. media reported on Friday.According to technology news site The Verge, at a recent analyst and investor meeting, Logitech chief executive officer Guerrino De Luca said the launch of Logitech Revue (with Google TV set-top box) last year was "a mistake of implementation of a gigantic nature."The project cost the company more than 100 million U.S. dollars in operating profit.He said the company had "brought closure to the Logitech Revue saga" and has "no plans to introduce another box to replace Revue" after the inventory runs out this quarter.The CEO also predicted that Google TV will have a chance sometime in the future, but it would be a "grandchild of Google TV " that would do it. Logitech has no plans to help make that happen.Launched during the holiday shopping season last year, the Logitech Revue with Google TV system was criticized for being pricey and unpolished although it gives consumers a streamlined experience of traditional TV content and online media. In August, Logitech slashed the price from 249 dollars to 99 dollars.Last month, Google introduced a redesigned Google TV after sales of the first version did not meet expectations.In April, Logitech reported that Revue with Google TV set-top box and related gear only brought five million dollars in sales during the first quarter of this year, 72 percent less than the company had expected.However, support from some leading TV manufacturers may still help Google fulfill its TV plan. A Bloomberg report said Friday that Google and LG Electronics, world's second-largest TV manufacturer, may unveil a television using the search giant's software at the upcoming Consumer Electronics Show in Las Vegas.Samsung, world's largest TV manufacturer, said in February that it was in discussions with Google to develop a TV product.

LOS ANGELES, Oct. 3 (Xinhua) -- An organizer of the World Stem Cell Summit says one of the key problems medical researchers face these days is how to apply their findings in the real world."How do you take the phenomenal scientific research going on in labs and translate it into medical treatments,?" said Bernie Siegel, the founder and co-chair of the summit and executive director of the Genetic Policy Institute, which organized the event."It's a big job to do this, and more than just the science," Siegel said, noting that in a growing field now moving beyond basic lab research, the aim is to connect the people who do the work with those who finance it.The three-day summit, which opened Monday in Pasadena, features more than 150 top international speakers and 50 hours of programming with leaders from science, pharmaceutics, business, policy, ethics, law and other fields.The cell therapy industry, a "nascent" field, has emerged to be a potentially multi-billion business with unlimited potential, Siegel said.Stephen Dalton, a University of Georgia professor, reported that one of the biggest developments in stem cell research in the past year was the realization that cells can be transdifferentiated from one state to another without returning to a pluripotent state.Dalton said the principle was previously supported by a few isolated examples but it was not until 2010 that the idea was widely accepted.Mark Sussman, a professor from San Diego State University, called the identification of lung stem cells from human tissue samples capable of regenerating the highly complex and specialized structures of mature lungs a breakthrough in lung biology and regenerative medicine.He said results presented by the Anversa group in the New England Journal of Medicine demonstrate that human lung stem cells can be expanded in vitro and also retain the capacity to integrate into adult tissue upon introduction into mice.The study, Sussman said, has opened up an entirely new field of possibilities for lung regeneration and potential therapeutic applications for many conditions where treatment options are either very limited or nonexistent.

BEIJING, Jan. 1 (Xinhua) -- State Grid Corporation of China (SGCC), the country's largest power supplier, said Sunday it has put to trial operation a cross-border electricity transmission project in northeastern Heilongjiang province to supply Chinese with Russia's electric power exports.The electric power SGCC purchased from Russia began reaching Chinese customers late Saturday night after the completion of the direct-current back-to-back networking substation, or called "the trans-Amur project" by Russians, SGCC said in a statement on its website.The trial operation will last 168 hours, SGCC said in the statement.With a transmission capacity of 750 mega-watts, the electricity transmission project is China's biggest cross-border power line, according to SGCC."The implementation of the project will gain experience for the expansion of Sino-Russian energy cooperation and help promote the economic development for both countries," SGCC said.The project is also part of the Sino-Russian energy and trade cooperation.Russian Deputy Energy Minister Andrei Shishkin said in June 2011 that the transmission project would increase Russia's power supply to five or six billion kilowatt hours of electricity to China and Russia intended to increase its electricity supply to China in the coming years.Russian companies plan export 60 billion kwh of electricity to China by 2020. Power plants will be built along its border with China to reduce power transmission losses and reduce transportation costs.Also on Sunday, an oil pipeline linking Russia's far east and northeast China witnessed its one year anniversary of operation, as operators announced an accumulated 15 million tonnes of oil had been transported into China in 2011.